Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012.

We aimed to describe changes in treatment patterns for clinical T3 prostate cancer (PCa) from 1998 to 2012, specifically investigating what factors influence receipt of prostatectomy or radiation.

Using the Surveillance, Epidemiology, and End Results database, we studied 11,604 men with clinical T3N0M0 PCa from 1998 to 2012, with treatment categorized as radiation, radical prostatectomy (RP), or no curative therapy.

We calculated rate of treatment type by year of diagnosis to investigate trends in treatment patterns, further stratifying by clinical T3a, defined as unilateral and bilateral extracapsular extension (n = 3,842), vs. T3b (defined as extension to seminal vesicles (n = 3,665). Finally, a multivariable logistic regression analysis measured association of demographic and clinical variables with type of treatment received for years 2010 to 2011.

Rates of prostatectomy increased significantly from 1998 to 2012 (12. 5% vs. 44. 4%), radiation decreased significantly (55. 8% vs. 38. 4%), and receipt of no treatment also decreased (31. 7% vs. 17. 2%, all P

Since 1998, there has been a significant increase in the use of RP for clinical T3 PCa and a significant decrease in the use of radiation such that in 2012, the use of prostatectomy exceeded the use of radiation.

Urologic oncology. 2015 Oct 14 [Epub ahead of print]

Michelle D Nezolosky, Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, Yu-Wei Chen, Clair J Beard, Toni K Choueiri, Neil E Martin, Christopher J Sweeney, Quoc-Dien Trinh, Paul L Nguyen

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women׳s Hospital, Boston, MA. , Harvard Medical School, Boston, MA. , Harvard Medical School, Boston, MA. , Department of Internal Medicine, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA. , Harvard T. H. Chan School of Public Health, Boston, MA. , Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women׳s Hospital, Boston, MA; Harvard Medical School, Boston, MA. , Harvard Medical School, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA. , Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women׳s Hospital, Boston, MA; Harvard Medical School, Boston, MA. , Harvard Medical School, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA. , Harvard Medical School, Boston, MA; Division of Urology, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA. , Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women׳s Hospital, Boston, MA; Harvard Medical School, Boston, MA. 

PubMed